Obermatt
See Similar Stocks →

Flags

Earnings warningFinancial distress

Agenus

NAQ:AGEN · US00847G8042
BiotechnologySmall

360

85
Medium confidence — indicative
Profit price1
Cash yield98
Price/Sales100
EV / Gross Profit89
Price/Book78
Returns on capital92
EBIT Margin85
Gross Profitability94
Accruals10
Owner Earnings Margin100
Sales growth72
Profit growth1
Reinvestment1
Price momentum6
Debt load6
Refinancing1
Debt Payback50
Liquidity87
Analyst ratings100
Expectations trend50
Market mood32
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Agenus clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1999
Employees149
Websiteagenusbio.com
ISINUS00847G8042
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Infectious DiseasesImmunologyOncologyVaccinesBiotechnologyMedical DeviceTherapeutics

Description

Agenus Inc. operates as a clinical-stage biotechnology company. The company focuses on discovering and developing immunotherapies for cancer and infectious disease. The primary business is immuno-oncology, where it advances antibody-based programs t…

Analysis

Middle-of-the-road

Agenus Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is attractive. You pay 2.0× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is mixed and the balance sheet is sturdy. The company scores 13/20 on our value-creation score: creating some value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
—
—
—
Price/Earnings
7
—
—
—
Price/Book
78
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
86
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Agenus with its peers
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Oric Pharmaceuticals
NSQ:ORIC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Arbutus Biopharma
NSQ:ABUS
43
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Voyager Therapeutics
NSQ:VYGR
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
CytomX Therapeutics
NSQ:CTMX
8
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nkarta
NSQ:NKTX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →